Arcturus Therapeutics Holdings, Inc. (ARCT)

Over the past six months, Arcturus Therapeutics' stock has experienced several notable events. In December 2025, ARCT stock plunged 59% in three months. In November 2025, Citigroup and Piper Sandler maintained their recommendations for ARCT, and the company reported Q3 2025 results with revenue declines and a net loss. In March 2026, Arcturus reported its Q4 and fiscal year 2025 financial results, with decreased research and development expenses and B. Riley Securities initiated coverage with a Buy recommendation. In May 2026, the company announced Q1 2026 financial results, reporting a revenue drop and a widened net loss, but reiterated a cash runway extending beyond Q2 2028. The European Commission granted marketing authorization for KOSTAIVE (Arct-154).

There is no explicit mention or indication of significant demand seasonality for Arcturus Therapeutics' products or services. Demand for its products is likely driven by disease prevalence, clinical trial success, regulatory approvals, and public health needs, rather than predictable seasonal patterns.

Arcturus Therapeutics is a biotechnology company specializing in mRNA medicines and vaccines, operating within the Biotechnology & Medical Research sector, specifically the pharmaceutical industry. The company uses its LUNAR® and STARR® technologies to develop RNA-based therapeutics and vaccines. Key products include KOSTAIVE® (ARCT-154), an approved self-amplifying mRNA COVID-19 vaccine, and mRNA therapeutic candidates such as ARCT-032 for cystic fibrosis, ARCT-810 for ornithine transcarbamylase deficiency, ARCT-2138 for seasonal influenza, and ARCT-2304 for pandemic influenza. Arcturus' platforms are versatile and can be applied to various nucleic acid medicines.

Arcturus Therapeutics is headquartered in San Diego, California, and has a global presence through collaborations and a joint venture in Japan, ARCALIS. They also have ongoing global collaborations with CSL Seqirus and U.S. BARDA for pandemic flu programs. The company's technologies are protected by an extensive patent portfolio with over 500 patents and patent applications across major jurisdictions, including the U.S., Europe, Japan, and China.

Arcturus Therapeutics' brand reputation is closely tied to its clinical development progress, regulatory achievements, and financial performance. The authorization of KOSTAIVE in Japan and the EU enhances its reputation. Positive interim Phase 2 data for its OTC deficiency program and the initiation of a Phase 2 study for cystic fibrosis also contribute positively. However, the company's stock performance, including a significant plunge in December 2025 and a reported revenue drop in Q1 2026, could negatively impact its financial reputation. Analyst ratings generally suggest a "Moderate Buy" consensus.

Arcturus Therapeutics is primarily owned by institutional shareholders (83.37%), with insiders holding 12.98% and retail investors 3.65%. The company has 128 institutional owners and shareholders holding a total of 24,313,230 shares. Major institutional owners include Federated Hermes, Inc., BlackRock, Inc., ARK Investment Management LLC, Sumitomo Mitsui Trust Holdings, Inc., Vanguard Group Inc, Nikko Asset Management Americas, Inc., Geode Capital Management, Llc, State Street Corp, Two Sigma Investments, Lp, and Two Sigma Advisers, Lp. Joseph E. Payne, the President, CEO, and Director of the board, is the largest individual shareholder.